Treatment of advanced ovarian carcinoma with a combination of hexamethylmelamine, cyclophosphamide, methotrexate, and 5-fluorouracil (Hexa-CAF) in patients with and without previous treatment

J. P. Neijt, A. C M van Lindert, C. P J Vendrik, K. J. Roozendaal, A. Struyvenberg, H. M. Pinedo

Research output: Contribution to journalArticlepeer-review

Abstract

Forty patients with stage III or IV epithelial ovarian tumors were treated with a combination of hexamethylmelamine, cyclophosphamide, methotrexate, and 5-fluorouracil. Fourteen of 37 evaluable patients had received previous treatment. Three of these 14 previously treated patients responded; no complete remissions were achieved and more severe toxicity was seen compared with the 23 previously untreated patients. In the latter group of patients, seven partial remissions and five complete remissions documented by peritoneoscopy and laparotomy were achieved. It is concluded that the combination of hexamethylmelamine, cyclophosphamide, methotrexate, and 5-fluorouracil is not useful as second-line chemotherapy but can be considered suitable for remission induction in previously untreated patients.

Original languageEnglish (US)
Pages (from-to)323-326
Number of pages4
JournalCancer Treatment Reports
Volume64
Issue number2-3
StatePublished - 1980
Externally publishedYes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Treatment of advanced ovarian carcinoma with a combination of hexamethylmelamine, cyclophosphamide, methotrexate, and 5-fluorouracil (Hexa-CAF) in patients with and without previous treatment'. Together they form a unique fingerprint.

Cite this